drugset / Trial / NCT05498480
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and drug levels of relatlimab combined with nivolumab in Chinese participants with advanced solid tumors.
Timeline
- Start
- 2022-07-27
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |